全文获取类型
收费全文 | 11411篇 |
免费 | 531篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 139篇 |
儿科学 | 131篇 |
妇产科学 | 105篇 |
基础医学 | 1435篇 |
口腔科学 | 247篇 |
临床医学 | 706篇 |
内科学 | 2657篇 |
皮肤病学 | 202篇 |
神经病学 | 923篇 |
特种医学 | 473篇 |
外科学 | 2327篇 |
综合类 | 45篇 |
一般理论 | 1篇 |
预防医学 | 406篇 |
眼科学 | 191篇 |
药学 | 946篇 |
中国医学 | 39篇 |
肿瘤学 | 1022篇 |
出版年
2021年 | 186篇 |
2020年 | 107篇 |
2019年 | 162篇 |
2018年 | 182篇 |
2017年 | 165篇 |
2016年 | 197篇 |
2015年 | 173篇 |
2014年 | 225篇 |
2013年 | 343篇 |
2012年 | 437篇 |
2011年 | 523篇 |
2010年 | 281篇 |
2009年 | 267篇 |
2008年 | 395篇 |
2007年 | 498篇 |
2006年 | 470篇 |
2005年 | 475篇 |
2004年 | 466篇 |
2003年 | 435篇 |
2002年 | 482篇 |
2001年 | 429篇 |
2000年 | 456篇 |
1999年 | 410篇 |
1998年 | 131篇 |
1997年 | 128篇 |
1996年 | 96篇 |
1995年 | 84篇 |
1994年 | 84篇 |
1993年 | 80篇 |
1992年 | 360篇 |
1991年 | 316篇 |
1990年 | 318篇 |
1989年 | 296篇 |
1988年 | 285篇 |
1987年 | 286篇 |
1986年 | 279篇 |
1985年 | 215篇 |
1984年 | 142篇 |
1983年 | 141篇 |
1982年 | 50篇 |
1981年 | 55篇 |
1979年 | 115篇 |
1978年 | 56篇 |
1977年 | 56篇 |
1974年 | 52篇 |
1973年 | 60篇 |
1972年 | 65篇 |
1971年 | 45篇 |
1970年 | 49篇 |
1969年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 28 毫秒
1.
Iwasa-Inoue Naomi Nomura Hiroyuki Kataoka Fumio Chiyoda Tatsuyuki Yoshihama Tomoko Nanki Yoshiko Sakai Kensuke Kobayashi Yusuke Yamagami Wataru Morisada Tohru Hirasawa Akira Aoki Daisuke 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(2):441-447
International Journal of Clinical Oncology - This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian,... 相似文献
2.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
3.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
4.
5.
Yu Akazawa Yuki Saito Toshiaki Yoshikawa Keigo Saito Kazuto Nosaka Manami Shimomura Shoichi Mizuno Yasunari Nakamoto Tetsuya Nakatsura 《Cancer science》2020,111(8):2736-2746
Lung cancer is the leading cause of cancer‐related deaths worldwide. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) often have good clinical activity against non–small cell lung cancer (NSCLC) with activating EGFR mutations. Osimertinib, which is a third‐generation EGFR‐TKI, has a clinical effect even on NSCLC harboring the threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation that causes TKI resistance. However, most NSCLC patients develop acquired resistance to osimertinib within approximately 1 year, and 40% of these patients have the EGFR T790M and cysteine to serine change at codon 797 (C797S) mutations. Therefore, there is an urgent need for the development of novel treatment strategies for NSCLC patients with the EGFR T790M/C797S mutation. In this study, we identified the EGFR T790M/C797S mutation‐derived peptide (790‐799) (MQLMPFGSLL) that binds the human leukocyte antigen (HLA)‐A*02:01, and successfully established EGFR T790M/C797S‐peptide‐specific CTL clones from human PBMC of HLA‐A2 healthy donors. One established CTL clone demonstrated adequate cytotoxicity against T2 cells pulsed with the EGFR T790M/C797S peptide. This CTL clone also had high reactivity against cancer cells that expressed an endogenous EGFR T790M/C797S peptide using an interferon‐γ (IFN‐γ) enzyme‐linked immunospot (ELISPOT) assay. In addition, we demonstrated using a mouse model that EGFR T790M/C797S peptide‐specific CTL were induced by EGFR T790M/C797S peptide vaccine in vivo. These findings suggest that an immunotherapy targeting a neoantigen derived from EGFR T790M/C797S mutation could be a useful novel therapeutic strategy for NSCLC patients with EGFR‐TKI resistance, especially those resistant to osimertinib. 相似文献
6.
7.
Katsunobu Oyama Sachio Fushida Tomoya Tsukada Jun Kinoshita Toshifumi Watanabe Masatoshi Shoji Shinichi Nakanuma Koichi Okamoto Seisho Sakai Isamu Makino Keishi Nakamura Hironori Hayashi Masafumi Inokuchi Hisatoshi Nakagawara Tomoharu Miyashita Hidehiro Tajima Hiroyuki Takamura Itasu Ninomiya Hirohisa Kitagawa Takashi Fujimura Ryousuke Tajiri Akishi Ooi Tetsuo Ohta 《Journal of gastroenterology》2015,50(1):121-122
8.
Masatoshi Morimoto Kosaku Higashino Hiroaki Manabe Fumitake Tezuka Kazuta Yamashita Yoichiro Takata Shoichiro Takao Toshinori Sakai Takashi Chikawa Akihiro Nagamachi Koichi Sairyo 《Journal of orthopaedic science》2019,24(1):50-56
Background
Despite facet joints being three-dimensional structures, previous computed tomography and magnetic resonance imaging studies have evaluated facet joint orientation in only the axial plane. Facet joint orientation in the sagittal plane has rarely been studied using these imaging techniques. The aim of this study was to elucidate facet joint orientation in both the axial and sagittal planes on computed tomography.Methods
A total of 568 patients (343 men, 225 women) (excluding orthopedic outpatients) for whom abdominal and pelvic computed tomography scans were obtained at our hospital between September 2010 and October 2012 were included. Mean age was 63 (range 21–90) years. Patients were divided into a degenerative spondylolisthesis group (67 patients; 30 men, 37 women) and a control group (313 patients; 313 men, 188 women). Facet joint orientation was evaluated in the control group according to patient age (≤50, 51–60, 61–70, or ≥71 years). The findings in the control group were then compared with those in the degenerative spondylolisthesis group. The orientation of the lumbar facet joints at each level was measured in the axial and sagittal planes on computed tomography images.Results
Facet joint angles decreased with age at L4/5 and L5/S1 in women in the axial plane and at L4/5 in men and L3/4 and L4/5 in women in the sagittal plane. The variation in facet joint angle was greatest at L4/5 in women. Patients with degenerative spondylolisthesis showed more sagittally and horizontally oriented facet joints in the axial and sagittal planes; facet tropism showed an association with degenerative spondylolisthesis in the axial plane.Conclusions
The axial and sagittal orientation of facet joints in the lower lumbar vertebra, especially L4/5, was negatively correlated with age. This finding could help to explain why older people are more prone to degenerative spondylolisthesis. 相似文献9.
10.
Tetsuji Terazawa Jin Matsuyama Masahiro Goto Ryohei Kawabata Shunji Endo Motohiro Imano Shoichiro Fujita Yusuke Akamaru Hirokazu Taniguchi Mitsutoshi Tatsumi Sang-Woong Lee Yoshitaka Kurisu Hisato Kawakami Yukinori Kurokawa Toshio Shimokawa Daisuke Sakai Takeshi Kato Kazumasa Fujitani Taroh Satoh 《The oncologist》2020,25(2):119-e208